Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blindness MILAN--(BUSINESS WIRE)-- On the heels of ...
Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...
GEN2, GenVivo’s first product candidate to enter clinical development, is a non-replicating mRNA gene therapy vector being developed as a cancer immunotherapy to both kill tumors and activate a ...
CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback